CAR-T Cell Therapy Market By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others), and By Region, Trends, Analysis and Forecast till 2034

Report Code: PMI1918 | Publish Date: April 2024 | No. of Pages: 180

Global CART Cell Therapy Market Companies

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Bluebird Bio-Inc.
  • Novartis AG
  • Caribou Biosciences Inc.
  • Celgene Corporation
  • Sorrento Therapeutics Inc.
  • Miltenyi Biotech
  • Cartesian Therapeutics

Recent News:

  • In addition to helping Legend Biotech and Johnson & Johnson develop clinical batches of CAR-T cell therapy "Carvykti" for the treatment of multiple myeloma disease, Novartis inked a three-year contract in April 2023 to manufacture the drug.
  • Gilead Sciences increased its market share in the cancer sector and generated $670 million in sales in the field in April 2023. Gilead Sciences is expected to back "Yescarta," a CAR-T cell treatment.
  • The Johnson & Johnson research data from April 2023 demonstrated the significant advantages of multiple myeloma cell treatment. According to the results, J&J and Legend's treatment, "Carvykti," can reduce the risk of disease development by almost 70% when compared to prescription medications.
  • AstraZeneca's cell therapy initiative produced a novel cancer target in November 2022, and the company plans to begin clinical studies. Early oncology clinical trial work by AstraZeneca demonstrated the presence of anti-Steap2 Car-T treatment, or "AZDO754."